• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study.

作者信息

Davidson Marta B, Rice Alexandra, Stewart Douglas, Owen Carolyn

机构信息

Princess Margaret Cancer Centre, Toronto, Canada.

Department of Family Medicine, University of British Columbia, Vancouver, Canada.

出版信息

Leuk Lymphoma. 2022 Dec;63(12):2996-2999. doi: 10.1080/10428194.2022.2102620. Epub 2022 Jul 25.

DOI:10.1080/10428194.2022.2102620
PMID:35875877
Abstract
摘要

相似文献

1
Generalizability of landmark clinical trials in diffuse large B cell lymphoma to real-world patients: a single-center retrospective cohort study.弥漫性大B细胞淋巴瘤标志性临床试验对真实世界患者的可推广性：一项单中心回顾性队列研究
Leuk Lymphoma. 2022 Dec;63(12):2996-2999. doi: 10.1080/10428194.2022.2102620. Epub 2022 Jul 25.
2
Interpretation of clinical trials in diffuse large-cell lymphoma.
J Clin Oncol. 1988 Aug;6(8):1335-47. doi: 10.1200/JCO.1988.6.8.1335.
3
Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.关于接受R-CHOP或R-CHOEP治疗的高危弥漫性大B细胞淋巴瘤年轻患者的真实世界数据——MYC、BCL2和BCL6作为预后生物标志物
PLoS One. 2017 Oct 31;12(10):e0186983. doi: 10.1371/journal.pone.0186983. eCollection 2017.
4
Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis.324例初治弥漫性大B细胞淋巴瘤患者的国际预后指数与NCCN-IPI比较：一项多中心回顾性分析
Leuk Lymphoma. 2016 May;57(5):1211-4. doi: 10.3109/10428194.2015.1079319. Epub 2015 Oct 12.
5
[Clinical manifestation and treatment of extranodal diffuse large B-cell lymphoma].[结外弥漫性大B细胞淋巴瘤的临床表现与治疗]
Rinsho Ketsueki. 2016;57(10):1991-1999. doi: 10.11406/rinketsu.57.1991.
6
[Value of interim 18F-FDG PET-CT examination in evaluation of chemotherapy response and prognosis in patients with diffuse large B-cell lymphoma].[18F-FDG PET-CT中期检查在弥漫性大B细胞淋巴瘤患者化疗反应评估及预后判断中的价值]
Zhonghua Xue Ye Xue Za Zhi. 2014 Apr;35(4):342-4. doi: 10.3760/cma.j.issn.0253-2727.2014.04.020.
7
Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials.HLA-DR 表达缺失和免疫母细胞形态预示弥漫性大 B 细胞淋巴瘤不良预后——来自两项前瞻性随机临床试验病例分析。
Haematologica. 2009 Nov;94(11):1569-80. doi: 10.3324/haematol.2009.008862.
8
Immunohistochemical prognostication in diffuse large B-cell lymphoma: a single center 6-year retrospective analysis.
Leuk Lymphoma. 2015;56(10):2975-7. doi: 10.3109/10428194.2015.1011158. Epub 2015 Mar 6.
9
Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.弥漫性大B细胞非霍奇金淋巴瘤的临床预后因素：一项回顾性研究。
J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.
10
Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.OCT-1 基因过表达是弥漫性大 B 细胞淋巴瘤（DLBCL）不良预后的生物标志物：来自 77 例巴西患者回顾性队列的数据。
BMC Cancer. 2020 Oct 29;20(1):1041. doi: 10.1186/s12885-020-07553-2.

引用本文的文献

1
One for the ages: impact of age on international prognostic indices in lymphoid cancer.献给岁月的研究：年龄对淋巴癌国际预后指数的影响
Blood Adv. 2025 Aug 26;9(16):4260-4264. doi: 10.1182/bloodadvances.2025016534.
2
A Real-World Data-Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B-Cell Lymphoma Patients.基于真实世界数据对弥漫性大B细胞淋巴瘤患者作为试验纳入标准一部分的预后指标进行分析。
Eur J Haematol. 2025 Jan;114(1):26-36. doi: 10.1111/ejh.14301. Epub 2024 Sep 10.